Which has better valuation & earnings, VCYT or TWST?

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.51 $66.35M $1.09 44.67 Twist Bioscience $376.57M 11.96 -$77.67M -$1.33 N/A

Does the media refer more to VCYT or FMS?

In the previous week, Veracyte had 13 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 16 mentions for Veracyte and 3 mentions for Fresenius Medical Care AG & Co. KGaA. Veracyte's average media sentiment score of 0.40 beat Fresenius Medical Care AG & Co. KGaA's score of -0.04 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Fresenius Medical Care AG & Co. KGaA 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor BTSG or VCYT?

In the previous week, Veracyte had 11 more articles in the media than BrightSpring Health Services. MarketBeat recorded 16 mentions for Veracyte and 5 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.15 beat Veracyte's score of 0.40 indicating that BrightSpring Health Services is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BrightSpring Health Services 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veracyte 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, VCYT or CELC?

Veracyte has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.51 $66.35M $1.09 44.67 Celcuity N/A N/A -$177.04M -$3.90 N/A

Is VCYT or CELC more profitable?

Veracyte has a net margin of 16.25% compared to Celcuity's net margin of 0.00%. Veracyte's return on equity of 9.07% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% Celcuity N/A -244.61% -50.22%

Does the media favor VCYT or CELC?

In the previous week, Celcuity had 3 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for Celcuity and 16 mentions for Veracyte. Veracyte's average media sentiment score of 0.40 beat Celcuity's score of -0.13 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Celcuity 2 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Neutral

Which has higher valuation and earnings, VCYT or PACS?

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $517.15M 7.51 $66.35M $1.09 44.67 PACS Group $5.29B 1.09 $191.54M $1.56 23.39

Is VCYT or PACS more profitable?

Veracyte has a net margin of 16.25% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% PACS Group 4.49% 26.47% 4.36%

Does the media prefer VCYT or PACS?

In the previous week, Veracyte had 15 more articles in the media than PACS Group. MarketBeat recorded 16 mentions for Veracyte and 1 mentions for PACS Group. Veracyte's average media sentiment score of 0.40 beat PACS Group's score of 0.00 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 3 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral PACS Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veracyte (VCYT) Competitors

$48.69 +0.89 (+1.86%)

Closing price 04:00 PM Eastern

Extended Trading

$49.75 +1.06 (+2.18%)

As of 06:37 PM Eastern

Compare

VCYT vs. TWST, FMS, BTSG, CELC, and PACS

Should you buy Veracyte stock or one of its competitors? MarketBeat compares Veracyte with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veracyte include Twist Bioscience (TWST), Fresenius Medical Care AG & Co. KGaA (FMS), BrightSpring Health Services (BTSG), Celcuity (CELC), and PACS Group (PACS). These companies are all part of the "medical" sector.

How does Veracyte compare to Twist Bioscience?

Veracyte (NASDAQ:VCYT) and Twist Bioscience (NASDAQ:TWST) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Veracyte has higher revenue and earnings than Twist Bioscience. Twist Bioscience is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.51	$66.35M	$1.09	44.67
Twist Bioscience	$376.57M	11.96	-$77.67M	-$1.33	N/A

Veracyte presently has a consensus target price of $47.57, suggesting a potential downside of 2.30%. Twist Bioscience has a consensus target price of $58.00, suggesting a potential downside of 19.81%. Given Veracyte's higher probable upside, equities analysts plainly believe Veracyte is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Veracyte had 15 more articles in the media than Twist Bioscience. MarketBeat recorded 16 mentions for Veracyte and 1 mentions for Twist Bioscience. Twist Bioscience's average media sentiment score of 1.38 beat Veracyte's score of 0.40 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Veracyte	Neutral
Twist Bioscience	Positive

Veracyte has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Veracyte has a net margin of 16.25% compared to Twist Bioscience's net margin of -19.85%. Veracyte's return on equity of 9.07% beat Twist Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Twist Bioscience	-19.85%	-26.73%	-19.15%

Summary

Veracyte beats Twist Bioscience on 10 of the 15 factors compared between the two stocks.

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Veracyte (NASDAQ:VCYT) and Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Veracyte has a net margin of 16.25% compared to Fresenius Medical Care AG & Co. KGaA's net margin of 4.88%. Veracyte's return on equity of 9.07% beat Fresenius Medical Care AG & Co. KGaA's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Fresenius Medical Care AG & Co. KGaA	4.88%	8.90%	4.05%

Veracyte presently has a consensus target price of $47.57, indicating a potential downside of 2.30%. Fresenius Medical Care AG & Co. KGaA has a consensus target price of $28.00, indicating a potential upside of 34.00%. Given Fresenius Medical Care AG & Co. KGaA's higher probable upside, analysts plainly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Fresenius Medical Care AG & Co. KGaA	5 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.44

Veracyte has a beta of 1.98, meaning that its stock price is 98% more volatile than the broader market. Comparatively, Fresenius Medical Care AG & Co. KGaA has a beta of 0.8, meaning that its stock price is 20% less volatile than the broader market.

In the previous week, Veracyte had 13 more articles in the media than Fresenius Medical Care AG & Co. KGaA. MarketBeat recorded 16 mentions for Veracyte and 3 mentions for Fresenius Medical Care AG & Co. KGaA. Veracyte's average media sentiment score of 0.40 beat Fresenius Medical Care AG & Co. KGaA's score of -0.04 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Fresenius Medical Care AG & Co. KGaA	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Veracyte. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.51	$66.35M	$1.09	44.67
Fresenius Medical Care AG & Co. KGaA	$22.20B	0.51	$1.11B	$1.90	11.00

8.4% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Veracyte beats Fresenius Medical Care AG & Co. KGaA on 12 of the 17 factors compared between the two stocks.

How does Veracyte compare to BrightSpring Health Services?

BrightSpring Health Services (NASDAQ:BTSG) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

Veracyte has a net margin of 16.25% compared to BrightSpring Health Services' net margin of 2.27%. BrightSpring Health Services' return on equity of 14.63% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BrightSpring Health Services	2.27%	14.63%	4.41%
Veracyte	16.25%	9.07%	8.38%

BrightSpring Health Services has higher revenue and earnings than Veracyte. BrightSpring Health Services is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BrightSpring Health Services	$12.91B	0.91	$190.67M	$1.41	43.18
Veracyte	$517.15M	7.51	$66.35M	$1.09	44.67

BrightSpring Health Services has a beta of 1.87, suggesting that its share price is 87% more volatile than the broader market. Comparatively, Veracyte has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market.

In the previous week, Veracyte had 11 more articles in the media than BrightSpring Health Services. MarketBeat recorded 16 mentions for Veracyte and 5 mentions for BrightSpring Health Services. BrightSpring Health Services' average media sentiment score of 1.15 beat Veracyte's score of 0.40 indicating that BrightSpring Health Services is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BrightSpring Health Services	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veracyte	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

BrightSpring Health Services currently has a consensus target price of $57.64, suggesting a potential downside of 5.32%. Veracyte has a consensus target price of $47.57, suggesting a potential downside of 2.30%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than BrightSpring Health Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BrightSpring Health Services	0 Sell rating(s)	0 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	3.12
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56

Summary

BrightSpring Health Services beats Veracyte on 8 of the 15 factors compared between the two stocks.

How does Veracyte compare to Celcuity?

Veracyte (NASDAQ:VCYT) and Celcuity (NASDAQ:CELC) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Veracyte has a net margin of 16.25% compared to Celcuity's net margin of 0.00%. Veracyte's return on equity of 9.07% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Celcuity	N/A	-244.61%	-50.22%

63.3% of Celcuity shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Comparatively, 13.3% of Celcuity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Veracyte has a beta of 1.98, suggesting that its share price is 98% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market.

In the previous week, Celcuity had 3 more articles in the media than Veracyte. MarketBeat recorded 19 mentions for Celcuity and 16 mentions for Veracyte. Veracyte's average media sentiment score of 0.40 beat Celcuity's score of -0.13 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Celcuity	2 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Neutral

Veracyte currently has a consensus price target of $47.57, suggesting a potential downside of 2.30%. Celcuity has a consensus price target of $152.09, suggesting a potential upside of 70.98%. Given Celcuity's stronger consensus rating and higher probable upside, analysts plainly believe Celcuity is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Veracyte has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.51	$66.35M	$1.09	44.67
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

Summary

Veracyte beats Celcuity on 10 of the 16 factors compared between the two stocks.

How does Veracyte compare to PACS Group?

Veracyte (NASDAQ:VCYT) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

Veracyte has a net margin of 16.25% compared to PACS Group's net margin of 4.49%. PACS Group's return on equity of 26.47% beat Veracyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
PACS Group	4.49%	26.47%	4.36%

Veracyte presently has a consensus target price of $47.57, indicating a potential downside of 2.30%. PACS Group has a consensus target price of $48.00, indicating a potential upside of 31.55%. Given PACS Group's stronger consensus rating and higher probable upside, analysts clearly believe PACS Group is more favorable than Veracyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

PACS Group has higher revenue and earnings than Veracyte. PACS Group is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$517.15M	7.51	$66.35M	$1.09	44.67
PACS Group	$5.29B	1.09	$191.54M	$1.56	23.39

In the previous week, Veracyte had 15 more articles in the media than PACS Group. MarketBeat recorded 16 mentions for Veracyte and 1 mentions for PACS Group. Veracyte's average media sentiment score of 0.40 beat PACS Group's score of 0.00 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	3 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
PACS Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Veracyte and PACS Group tied by winning 7 of the 14 factors compared between the two stocks.

Get Veracyte News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VCYT vs. The Competition

Export

Metric	Veracyte	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.81B	$7.25B	$6.47B	$12.54B
Dividend Yield	N/A	1.23%	2.69%	5.22%
P/E Ratio	44.67	45.06	22.39	24.18
Price / Sales	7.51	74.02	520.79	112.26
Price / Cash	32.09	24.22	41.34	57.13
Price / Book	2.94	7.15	9.84	6.72
Net Income	$66.35M	$159.22M	$3.57B	$337.19M
7 Day Performance	9.44%	0.91%	-1.16%	0.48%
1 Month Performance	47.14%	3.99%	3.85%	5.07%
1 Year Performance	83.74%	1.56%	27.40%	34.25%

Veracyte Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VCYT Veracyte	1.6773 of 5 stars	$48.69 +1.9%	$47.57 -2.3%	+78.8%	$3.81B	$517.15M	44.67	790	Analyst Upgrade
TWST Twist Bioscience	1.4119 of 5 stars	$60.57 flat	$58.00 -4.2%	+125.8%	$3.77B	$376.57M	N/A	990	Positive News
FMS Fresenius Medical Care AG & Co. KGaA	4.6621 of 5 stars	$21.70 +0.3%	$28.00 +29.1%	-28.7%	$12.09B	$22.20B	11.42	1,488
BTSG BrightSpring Health Services	4.2751 of 5 stars	$58.50 flat	$57.00 -2.6%	+148.0%	$11.34B	$12.91B	41.49	23,500	Positive News Analyst Forecast
CELC Celcuity	3.1103 of 5 stars	$138.23 flat	$149.30 +8.0%	+686.7%	$6.74B	N/A	N/A	40	Trending News Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VCYT) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veracyte (VCYT) Competitors

VCYT vs. TWST, FMS, BTSG, CELC, and PACS

How does Veracyte compare to Twist Bioscience?

Summary

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Summary

How does Veracyte compare to BrightSpring Health Services?

Summary

How does Veracyte compare to Celcuity?

Summary

How does Veracyte compare to PACS Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veracyte (VCYT) Competitors

VCYT vs. TWST, FMS, BTSG, CELC, and PACS

How does Veracyte compare to Twist Bioscience?

Which has better valuation & earnings, VCYT or TWST?

Do analysts recommend VCYT or TWST?

Does the media refer more to VCYT or TWST?

Which has more risk & volatility, VCYT or TWST?

Is VCYT or TWST more profitable?

Summary

How does Veracyte compare to Fresenius Medical Care AG & Co. KGaA?

Is VCYT or FMS more profitable?

Do analysts recommend VCYT or FMS?

Which has more risk & volatility, VCYT or FMS?

Does the media refer more to VCYT or FMS?

Which has higher valuation & earnings, VCYT or FMS?

Do institutionals & insiders have more ownership in VCYT or FMS?

Summary

How does Veracyte compare to BrightSpring Health Services?

Is BTSG or VCYT more profitable?

Which has better earnings and valuation, BTSG or VCYT?

Which has more volatility and risk, BTSG or VCYT?

Does the media favor BTSG or VCYT?

Do analysts rate BTSG or VCYT?

Summary

How does Veracyte compare to Celcuity?

Is VCYT or CELC more profitable?

Do institutionals & insiders hold more shares of VCYT or CELC?

Which has more risk & volatility, VCYT or CELC?

Does the media favor VCYT or CELC?

Do analysts prefer VCYT or CELC?

Which has preferable valuation & earnings, VCYT or CELC?

Summary

How does Veracyte compare to PACS Group?

Is VCYT or PACS more profitable?

Do analysts rate VCYT or PACS?

Which has higher valuation and earnings, VCYT or PACS?

Does the media prefer VCYT or PACS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VCYT vs. The Competition

Veracyte Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools